scorecardresearch
Add as a preferred source on Google
Monday, November 10, 2025
TopicCorbevax

Topic: Corbevax

DCGI approval in, but here’s why you can’t choose Corbevax as your booster just yet

Corbevax was, over the weekend, approved for heterologous use as a Covid booster shot by apex drug regulator Drugs Controller General of India.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

Cleared Corbevax for ages 12-14 based on interim safety & immune response data, govt tells LS

Govt was responding to question on availability of safety & efficacy data for Corbevax, and whether it had been peer-reviewed. It sidestepped queries on efficacy & peer-review.

Corbevax is India’s ‘lowest priced vaccine’, saves exchequer Rs 1500 cr, Biological E says

Hyderabad-based Biological E has priced its vaccine at Rs 990 in the private market. For the government, however, the vaccine is at just Rs 145, making it very affordable.

DCGI gives emergency use approval to Biological E’s Corbevax vaccine for kids aged 12-18

It is the second Covid vaccine to get approval for use in children in India after Bharat Biotech's Covaxin.

Govt panel recommends Biological E’s Corbevax for emergency use among 12 to 18-year-olds

The recommendation has been sent to Drug Controller General of India for final approval. DCGI had earlier approved Corbevax for restricted use in emergency situations for adults.

5 months after nod, ZyCov-D set for rollout in 7 states. Bihar starts getting 1st set of shots

It will be used in six other states too. Corbevax of Biological E is also expected to start coming in this month. No decision so far on the government procuring Covovax.

Corbevax, a new patent-free Covid vaccine, is an important step to end pandemic

Corbevax was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine.

What it will take to vaccinate the world against Covid

A Q&A with vaccine scientist Peter Hotez, author of 'Preventing the Next Pandemic', on developing a low-cost Covid vaccine, and why Omicron won’t be the end of the pandemic.

Corbevax maker says ‘too much dependence on MNCs, focus on new tech’ behind vaccine inequity

Corbevax co-developer Dr Peter Hotez says the vaccine will 'make up for lost time' in race to immunise millions and its patent was waived in the spirit of 'decolonisation'.

On Camera

The govt’s ‘fix’ to speed up insolvency could add at least a year to the process

The proposed amendment to the Insolvency and Bankruptcy Code aims to reduce timelines and provide for a mechanism that involves minimal interaction with the court. It fails on both counts.

No more text-heavy ads, wider scope of services—ICAI’s ethics code overhaul to promote Indian CA firms

Open to public feedback until 26 November, the revised guidelines, among other changes, give CA firms more flexibility to advertise & promote their services.

‘Let them see’: Putin says new nuclear-powered missiles in the making, in message to Washington

At a ceremony felicitating Russian military engineers, Putin highlights Moscow’s 'parity' in defence technologies for the next century.

Bihar is where politics moves, and everything else stands still

Bihar is blessed with a land more fertile for revolutions than any in India. Why has it fallen so far behind then? Constant obsession with politics is at the root of its destruction.